This research demonstrates the in silico development of pyruvic acid derivatives targeting COX-2, suggesting potential analgesic and anti-inflammatory benefits.
Key Points
Compound H6 and H8 showed optimal characteristics, supporting their development as analgesic agents.
Molecular docking revealed superior binding affinities for several pyruvic acid derivatives compared to paracetamol.
Toxicity profiles predicted lower risks for compounds H8 and H10, highlighting their potential as safer alternatives.
All tested derivatives met drug-likeness criteria, indicating they could progress in the drug development pipeline.